MedTech M&A deal sizes lag behind Biotech

Top 10 MedTech M&A deals dominated by US targets! 

The top 10 MedTech M&A deals (by ticket size) range from EUR 22.5bn to EUR 4.1bn, with an average deal size of EUR 11bn. With 9 out of the top 10, the ranking is dominated US target companies. The largest deal was the acquisition of St. Jude Medical by Abbott in January 2017 for EUR 22.47bn.

By comparison, the top 10 Biotech M&A deals posted two weeks ago ranged between EUR 72.4bn and EUR 10.2bn with an average deal size of EUR 32bn, showing the significant difference to the top 10 MedTech M&A deals.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: